What is included in the patient preparation for instilling colloidal P32 chromic phosphate into the peritoneal cavity?

What is included in the patient preparation for instilling colloidal P32 chromic phosphate into the peritoneal cavity?

• A. Surgical placement of a LeVeen shunt to remove excess peritoneal fluid
• B. Fasting for 8-12 hours before radiopharmaceutical administration
• C. Administering antacid 2-4 hrs before the procedure
• D. Introducing 99mTc sulfur colloid into the cavity to confirm that the P32 will disperse evenly

Answer: (D)

The process of instilling colloidal P32 chromic phosphate into the peritoneal cavity involves critical preparation steps to ensure the successful delivery and distribution of the radiopharmaceutical. One of these steps is the introduction of a radiotracer, such as 99mTc sulfur colloid, into the peritoneal cavity. This serves to confirm that the distribution of the P32 will be uniform and effective throughout the area. By performing this test with 99mTc sulfur colloid, the physician can visualize the dispersal pattern of the colloid, which helps in predicting how well the P32 will spread in the peritoneal cavity upon administration. If the colloid shows an even distribution, it indicates that the conditions are suitable for the P32, thereby improving the effectiveness of the treatment. Fasting for several hours, placement of a shunt, and administering antacids may be common practices in certain medical procedures, but they do not pertain specifically to ensuring the effective application of P32 in this context. The focal point in preparation for the use of colloidal P32 chromic phosphate is to confirm that the radiopharmaceutical will disperse well in the patient's peritoneal cavity, making the use of 99mTc sulfur

The process of instilling colloidal P32 chromic phosphate into the peritoneal cavity involves critical preparation steps to ensure the successful delivery and distribution of the radiopharmaceutical. One of these steps is the introduction of a radiotracer, such as 99mTc sulfur colloid, into the peritoneal cavity. This serves to confirm that the distribution of the P32 will be uniform and effective throughout the area.

By performing this test with 99mTc sulfur colloid, the physician can visualize the dispersal pattern of the colloid, which helps in predicting how well the P32 will spread in the peritoneal cavity upon administration. If the colloid shows an even distribution, it indicates that the conditions are suitable for the P32, thereby improving the effectiveness of the treatment.

Fasting for several hours, placement of a shunt, and administering antacids may be common practices in certain medical procedures, but they do not pertain specifically to ensuring the effective application of P32 in this context. The focal point in preparation for the use of colloidal P32 chromic phosphate is to confirm that the radiopharmaceutical will disperse well in the patient's peritoneal cavity, making the use of 99mTc sulfur